Qualigen Corp (QLGN): Price-to-Revenue Multiple

A critical risk for Qualigen Therapeutics (QLGN) remains a severe liquidity shortage and the threat of bankruptcy. However, management is focused on a breakthrough in oncology treatment, while the shift toward formula licensing enhances profitability. The divergence of the P/S ratio from its historical average demonstrates current valuation dynamics, where the 1.50 mark serves as a relevant support level, capturing market value relative to revenue.

The P/S ratio determines the market value of a business relative to its annual sales volume, allowing for the identification of an undervalued asset or the risk of overpayment in the event of declining revenues. By analyzing the revenue-based valuation of Qualigen Therapeutics (QLGN), an investor can see the stability of the capitalization, which is bolstered by M&A potential driven by strategic partnerships in the development of small-molecule antiviral and oncology drugs.